0001209191-22-061947.txt : 20221219 0001209191-22-061947.hdr.sgml : 20221219 20221219164227 ACCESSION NUMBER: 0001209191-22-061947 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221215 FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Janku Filip CENTRAL INDEX KEY: 0001862930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 221471643 MAIL ADDRESS: STREET 1: MONTE ROSA THERAPEUTICS, INC. STREET 2: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-15 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001862930 Janku Filip MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 7.56 2022-12-15 4 A 0 36000 0.00 A 2032-10-02 Common Stock 36000 36000 D On October 3, 2022, the Reporting Person was granted an option to purchase 36,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On December 15, 2022, the performance criteria underlying such shares were met. The shares underlying this option shall vest in full on June 15, 2024, subject to the Reporting Person's continued service on such date. /s/ Ajim Tamboli, Attorney-in-Fact 2022-12-19